These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15663915)

  • 21. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D
    Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction.
    Schäfer A; Fraccarollo D; Hildemann SK; Tas P; Ertl G; Bauersachs J
    Cardiovasc Res; 2003 Jun; 58(3):655-62. PubMed ID: 12798439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spironolactone in congestive heart failure.
    Soberman JE; Weber KT
    Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective aldosterone blockade with eplerenone in patients with congestive heart failure.
    Salam AM
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1423-7. PubMed ID: 12882627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eplerenone: a selective aldosterone blocker.
    Stier CT
    Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
    Pitt B
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):145-9. PubMed ID: 7786835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
    Shah NC; Pringle S; Struthers A
    J Renin Angiotensin Aldosterone Syst; 2006 Mar; 7(1):20-30. PubMed ID: 17083070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES).
    Hauben M; Reich L; Gerrits CM; Madigan D
    Drug Saf; 2007; 30(12):1143-9. PubMed ID: 18035866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES.
    Bauersachs J; Fraccarollo D; Ertl G; Gretz N; Wehling M; Christ M
    Circulation; 2000 Nov; 102(19):2325-8. PubMed ID: 11067783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
    Zannad F; Dousset B; Alla F
    Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
    Hameedi A; Chadow HL
    Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of spironolactone treatment in patients with heart failure.
    Anton C; Cox AR; Watson RD; Ferner RE
    J Clin Pharm Ther; 2003 Aug; 28(4):285-7. PubMed ID: 12911680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eplerenone: a selective aldosterone receptor antagonist (SARA).
    Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
    Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RALES, EPHESUS and redox.
    Funder JW
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):121-5. PubMed ID: 15860254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.